Axsome Therapeutics Q3 net product revenue jumps 63%

Axsome Therapeutics

03/11/2025 12:07

Overview

Axsome Q3 2025 net product revenue grows 63% yr/yr to $171 mln

AUVELITY Q3 2025 sales rise 69% yr/yr to $136.1 mln

Company submits sNDA for AXS-05 in Alzheimer's agitation to FDA

Outlook

Axsome plans to initiate multiple Phase 3 trials in 4Q 2025

Company expects cash to fund operations into cash flow positivity

Axsome submitted sNDA for AXS-05 in Alzheimer's disease agitation

Result Drivers

AUVELITY SALES - AUVELITY sales increased 69% yr/yr to $136.1 mln, driven by expanded payer coverage and increased prescriptions

SUNOSI REVENUE - SUNOSI revenue grew 35% yr/yr to $32.8 mln, supported by increased prescriptions and royalty revenue

SYMBRAVO LAUNCH - SYMBRAVO generated $2.1 mln in its first full quarter post-launch, contributing to overall revenue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$47.22 mln
Q3 Operating Expenses
$217.10 mln
Q3 Operating Income
-$46.10 mln
Q3 Pretax Profit
-$47.22 mln


Press Release: ID:nGNX1ZY19D

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)